Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.8	3.38	18.35	36.56	33.41	11.89
Cash & Cash Equivalents	2.8	3.38	18.35	36.56	33.41	11.89
Cash Growth	-75.53%	-81.59%	-49.82%	9.44%	181.08%	-32.10%
Other Current Assets	2.04	4.07	6.07	4.38	2.06	2.13
Total Current Assets	4.84	7.44	24.41	40.94	35.47	14.02
Property, Plant & Equipment	0.09	0.1	0.17	0.09	1.33	1.29
Other Long-Term Assets	1.24	1.26	3.47	2.1	0	0
Total Long-Term Assets	1.33	1.36	3.64	2.19	1.33	1.29
Total Assets	6.17	8.81	28.05	43.14	36.8	15.31
Accounts Payable	5.2	3.54	2.56	2.12	0.51	0.89
Other Current Liabilities	3.15	4.62	4.95	3.3	1.97	1.53
Total Current Liabilities	8.35	8.16	7.51	5.41	2.49	2.42
Long-Term Debt	0.02	0.04	0.11	0.03	1.06	1.19
Total Long-Term Liabilities	0.02	0.04	0.11	0.03	1.06	1.19
Total Liabilities	8.37	8.2	7.62	5.44	3.54	3.61
Total Debt	0.02	0.04	0.11	0.03	1.06	1.19
Debt Growth	-73.75%	-65.09%	253.33%	-97.16%	-11.25%	-
Retained Earnings	-431.23	-428.28	-405.73	-384.53	-366.07	-357.63
Comprehensive Income	-0.9	-0.91	-1.32	-0.75	-0.75	-0.82
Shareholders' Equity	-2.21	0.61	15.94	37.69	33.26	11.7
Net Cash / Debt	2.78	3.34	18.24	36.53	32.35	10.69
Net Cash / Debt Growth	-75.54%	-81.68%	-50.07%	12.92%	202.50%	-38.91%
Net Cash Per Share	-	-	24.31	61.39	133.55	196.56
Working Capital	-3.52	-0.72	16.9	35.53	32.98	11.6
Book Value Per Share	-1.67	0.72	21.24	63.34	137.31	215.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).